Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Interesting GGP has a right of last refusal, rather than right of first refusal for Havieron. Does that mean we basically can match any offer and be guaranteed to buy it if we want to? Or could Newmont still decide to go with someone else?
Good to see work on the bispecific antibody format moving forward, I especially like the bullish statement from LD that it demonstrates ‘strong anti-tumour killing with no associated toxicity’.
Do you think we will get another RNS later in the week with details or do you think that is all we get at this moment in time?
Why is there only a tacit mention of the ImmunoBody platform (in passing, regarding Covid-19). There is zero mention of the SCIB1 study, results from that? Other companies mentioned in here talk about clinical trials etc, but this doesn't even mention the fact that Modi-1 is in the clinic and SCIB1 has incredible results in melanoma.
What is also interesting is if you compare how much other companies have raised. Scancell has done very well to have done what it has, over nearly 30 years, on £82m raised to date.
Pressed send too quickly - Opdivo/nivolumab (the Bristol Myers Squibb's version of keytruda) also comes off patent in 2028.
Yervoy/Ipilimumab also comes off patent this year.
These three are the checkpoint inhibitors used for melanoma.
Last update on the Clinical Trials site added Southampton University Hospitals Trust as now recruiting (31th Jan) with Ioannis Karydis as the site lead.
Here are two really interesting articles regarding the manufacturing hurdles for mRNA both in terms of manufacturing and also quality control.
https://www.ttp.com/insights/personalised-mrna-therapies-pose-a-qc-challenge/?utm_campaign=LS-CGT-BIO-brand-awareness&utm_content=175985657&utm_medium=social&utm_source=linkedin&hss_channel=lcp-122597
https://www.ttp.com/insights/with-personalised-cancer-vaccines-on-the-rise-is-manufacturing-scalable-yet/
Interesting to see the progression in the right direction! Seems CPI+Modi-1 may indeed be the way to go (caveat N=1). Hopefully not long until we get further news on the Modify trial in more detail. I’m so interested to hear about the pre/post surgery arm results to see what is actually happening inside these tumours.
Add to what Bermuda has said.
You can also profile the status of T-cells within these patient samples, so those expressing low levels of certain surface markers such as CD44, LY6C and killer cell lectin-like receptor subfamily G member 1 (KLRG1), could be a sign of T-cell exhaustion in the CD8 population.
The presence of regulatory T-cells could also be a sign that the immune system is preventing the full T-cell function within the tumour in specific patients, suppressing the anti-tumour response.
Website does say the following: 'These five mAbs are undergoing preclinical characterisation, with target validation underway for a number of other mAbs to add to the growing portfolio.' So I'm curious as to how much work is ongoing in this area.
Something which I don't think we hear much about though is SCLPs ability to generate more glycan mAbs. I know we hear a lot about the ones we have already generated, but I'm curious as to whether we have any background work going on trying to identify more glycan mabs.